Simple Measurement of IgA Predicts Immunity and Mortality in Ataxia-Telangiectasia.
Adolescent
Adult
Ataxia Telangiectasia
/ immunology
B-Lymphocytes
/ immunology
Child
Child, Preschool
Female
Humans
IgA Deficiency
/ immunology
IgG Deficiency
/ immunology
Immunoglobulin A
/ blood
Immunoglobulin G
/ blood
Immunoglobulin M
/ blood
Infant
Lymphocyte Count
Male
Middle Aged
T-Lymphocyte Subsets
/ immunology
Young Adult
Ataxia-telangiectasia
IgA deficiency
Immunodeficiency
Immunoglobulins
Lymphopenia
Mortality
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
28
01
2021
accepted:
25
06
2021
pubmed:
4
9
2021
medline:
19
2
2022
entrez:
3
9
2021
Statut:
ppublish
Résumé
Patients with ataxia-telangiectasia (A-T) suffer from progressive cerebellar ataxia, immunodeficiency, respiratory failure, and cancer susceptibility. From a clinical point of view, A-T patients with IgA deficiency show more symptoms and may have a poorer prognosis. In this study, we analyzed mortality and immunity data of 659 A-T patients with regard to IgA deficiency collected from the European Society for Immunodeficiencies (ESID) registry and from 66 patients with classical A-T who attended at the Frankfurt Goethe-University between 2012 and 2018. We studied peripheral B- and T-cell subsets and T-cell repertoire of the Frankfurt cohort and survival rates of all A-T patients in the ESID registry. Patients with A-T have significant alterations in their lymphocyte phenotypes. All subsets (CD3, CD4, CD8, CD19, CD4/CD45RA, and CD8/CD45RA) were significantly diminished compared to standard values. Patients with IgA deficiency (n = 35) had significantly lower lymphocyte counts compared to A-T patients without IgA deficiency (n = 31) due to a further decrease of naïve CD4 T-cells, central memory CD4 cells, and regulatory T-cells. Although both patient groups showed affected TCR-ß repertoires compared to controls, no differences could be detected between patients with and without IgA deficiency. Overall survival of patients with IgA deficiency was significantly diminished. For the first time, our data show that patients with IgA deficiency have significantly lower lymphocyte counts and subsets, which are accompanied with reduced survival, compared to A-T patients without IgA deficiency. IgA, a simple surrogate marker, is indicating the poorest prognosis for classical A-T patients. Both non-interventional clinical trials were registered at clinicaltrials.gov 2012 (Susceptibility to infections in ataxia-telangiectasia; NCT02345135) and 2017 (Susceptibility to Infections, tumor risk and liver disease in patients with ataxia-telangiectasia; NCT03357978).
Identifiants
pubmed: 34477998
doi: 10.1007/s10875-021-01090-8
pii: 10.1007/s10875-021-01090-8
pmc: PMC8604875
doi:
Substances chimiques
Immunoglobulin A
0
Immunoglobulin G
0
Immunoglobulin M
0
Banques de données
ClinicalTrials.gov
['NCT03357978', 'NCT02345135']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1878-1892Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
Boder E, Sedgwick RP. Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics. 1958;21:526–54.
pubmed: 13542097
Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016;11:159. https://doi.org/10.1186/s13023-016-0543-7 .
doi: 10.1186/s13023-016-0543-7
pubmed: 27884168
pmcid: 5123280
Schroeder SA, Zielen S. Infections of the respiratory system in patients with ataxia-telangiectasia. Pediatr Pulmonol. 2014;49:389–99. https://doi.org/10.1002/ppul.22817 .
doi: 10.1002/ppul.22817
pubmed: 23761391
Nissenkorn A, Levy-Shraga Y, Banet-Levi Y, Lahad A, Sarouk I, Modan-Moses D. Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort. Pediatr Res. 2016;79:889–94. https://doi.org/10.1038/pr.2016.19 .
doi: 10.1038/pr.2016.19
pubmed: 26891003
Pommerening H, van Dullemen S, Kieslich M, Schubert R, Zielen S, Voss S. Body composition, muscle strength and hormonal status in patients with ataxia telangiectasia: a cohort study. Orphanet J Rare Dis. 2015;10:155. https://doi.org/10.1186/s13023-015-0373-z .
doi: 10.1186/s13023-015-0373-z
pubmed: 26645295
pmcid: 4673730
Schubert R, Reichenbach J, Zielen S. Growth factor deficiency in patients with ataxia telangiectasia. Clin Exp Immunol. 2005;140:517–9. https://doi.org/10.1111/j.1365-2249.2005.02782.x .
doi: 10.1111/j.1365-2249.2005.02782.x
pubmed: 15932513
pmcid: 1809398
Voss S, Pietzner J, Hoche F, Taylor AMR, Last JI, Schubert R, Zielen S. Growth retardation and growth hormone deficiency in patients with Ataxia telangiectasia. Growth Factors. 2014;32:123–9. https://doi.org/10.3109/08977194.2014.939805 .
doi: 10.3109/08977194.2014.939805
pubmed: 25060036
Donath H, Woelke S, Theis M, Heß U, Knop V, Herrmann E, et al. Progressive liver disease in patients with ataxia telangiectasia. Front Pediatr. 2019;7:458. https://doi.org/10.3389/fped.2019.00458 .
doi: 10.3389/fped.2019.00458
pubmed: 31788461
pmcid: 6856634
Micol R, Ben Slama L, Suarez F, Le Mignot L, Beauté J, Mahlaoui N, et al. Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. J Allergy Clin Immunol. 2011;128:382-9.e1. https://doi.org/10.1016/j.jaci.2011.03.052 .
doi: 10.1016/j.jaci.2011.03.052
pubmed: 21665257
Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, Carson KA, Lederman HM. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr. 2004;144:505–11. https://doi.org/10.1016/j.jpeds.2003.12.046 .
doi: 10.1016/j.jpeds.2003.12.046
pubmed: 15069401
Schubert R, Reichenbach J, Zielen S. Deficiencies in CD4+ and CD8+ T cell subsets in ataxia telangiectasia. Clin Exp Immunol. 2002;129:125–32. https://doi.org/10.1046/j.1365-2249.2002.01830.x .
doi: 10.1046/j.1365-2249.2002.01830.x
pubmed: 12100032
pmcid: 1906431
Reichenbach J, Schubert R, Feinberg J, Beck O, Rosewich M, Rose MA, Zielen S. Impaired interferon-gamma production in response to live bacteria and Toll-like receptor agonists in patients with ataxia telangiectasia. Clin Exp Immunol. 2006;146:381–9. https://doi.org/10.1111/j.1365-2249.2006.03221.x .
doi: 10.1111/j.1365-2249.2006.03221.x
pubmed: 17100756
pmcid: 1810411
Schubert R, Reichenbach J, Rose M, Zielen S. Immunogenicity of the seven valent pneumococcal conjugate vaccine in patients with ataxia-telangiectasia. Pediatr Infect Dis J. 2004;23:269–70.
doi: 10.1097/01.inf.0000115737.35353.55
Driessen GJ, Ijspeert H, Weemaes CMR, Haraldsson Á, Trip M, Warris A, et al. Antibody deficiency in patients with ataxia telangiectasia is caused by disturbed B- and T-cell homeostasis and reduced immune repertoire diversity. J Allergy Clin Immunol. 2013;131:1367-75.e9. https://doi.org/10.1016/j.jaci.2013.01.053 .
doi: 10.1016/j.jaci.2013.01.053
pubmed: 23566627
Giovannetti A, Mazzetta F, Caprini E, Aiuti A, Marziali M, Pierdominici M, et al. Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia. Blood. 2002;100:4082–9. https://doi.org/10.1182/blood-2002-03-0976 .
doi: 10.1182/blood-2002-03-0976
pubmed: 12393664
Bagley J, Singh G, Iacomini J. Regulation of oxidative stress responses by ataxia-telangiectasia mutated is required for T cell proliferation. J Immunol. 2007;178:4757–63. https://doi.org/10.4049/jimmunol.178.8.4757 .
doi: 10.4049/jimmunol.178.8.4757
pubmed: 17404255
Matei IR, Gladdy RA, Nutter LMJ, Canty A, Guidos CJ, Danska JS. ATM deficiency disrupts Tcra locus integrity and the maturation of CD4+CD8+ thymocytes. Blood. 2007;109:1887–96. https://doi.org/10.1182/blood-2006-05-020917 .
doi: 10.1182/blood-2006-05-020917
pubmed: 17077325
Carney EF, Srinivasan V, Moss PA, Taylor AM. Classical ataxia telangiectasia patients have a congenitally aged immune system with high expression of CD95. J Immunol. 2012;189:261–8. https://doi.org/10.4049/jimmunol.1101909 .
doi: 10.4049/jimmunol.1101909
pubmed: 22649200
van Os NJH, Jansen AFM, van Deuren M, Haraldsson A, van Driel NTM, Etzioni A, et al. Ataxia-telangiectasia: immunodeficiency and survival. Clin Immunol. 2017;178:45–55. https://doi.org/10.1016/j.clim.2017.01.009 .
doi: 10.1016/j.clim.2017.01.009
pubmed: 28126470
Verhagen MMM, Last JI, Hogervorst FBL, Smeets DFCM, Roeleveld N, Verheijen F, et al. Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study. Hum Mutat. 2012;33:561–71. https://doi.org/10.1002/humu.22016 .
doi: 10.1002/humu.22016
pubmed: 22213089
Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: The next generation of ATM functions. Blood. 2013;121:4036–45. https://doi.org/10.1182/blood-2012-09-456897 .
doi: 10.1182/blood-2012-09-456897
pubmed: 23440242
pmcid: 3709651
Barlow C, Dennery PA, Shigenaga MK, Smith MA, Morrow JD, Roberts LJ, et al. Loss of the ataxia-telangiectasia gene product causes oxidative damage in target organs. Proc Natl Acad Sci U S A. 1999;96:9915–9. https://doi.org/10.1073/pnas.96.17.9915 .
doi: 10.1073/pnas.96.17.9915
pubmed: 10449794
pmcid: 22310
Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, Hamaguchi I, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature. 2004;431:997–1002. https://doi.org/10.1038/nature02989 .
doi: 10.1038/nature02989
pubmed: 15496926
Reichenbach J, Schubert R, Schindler D, Müller K, Böhles H, Zielen S. Elevated oxidative stress in patients with ataxia telangiectasia. Antioxid Redox Signal. 2002;4:465–9. https://doi.org/10.1089/15230860260196254 .
doi: 10.1089/15230860260196254
pubmed: 12215213
Barlow C, Eckhaus MA, Schäffer AA, Wynshaw-Boris A. Atm haploinsufficiency results in increased sensitivity to sublethal doses of ionizing radiation in mice. Nat Genet. 1999;21:359–60. https://doi.org/10.1038/7684 .
doi: 10.1038/7684
pubmed: 10192382
Woelke S, Valesky E, Bakhtiar S, Pommerening H, Pfeffermann LM, Schubert R, Zielen S. Treatment of granulomas in patients with ataxia telangiectasia. Front Immunol. 2018;9:2000. https://doi.org/10.3389/fimmu.2018.02000 .
doi: 10.3389/fimmu.2018.02000
pubmed: 30279689
pmcid: 6153364
Krauthammer A, Lahad A, Goldberg L, Sarouk I, Weiss B, Somech R, et al. Elevated IgM levels as a marker for a unique phenotype in patients with Ataxia telangiectasia. BMC Pediatr. 2018;18:185. https://doi.org/10.1186/s12887-018-1156-1 .
doi: 10.1186/s12887-018-1156-1
pubmed: 29866155
pmcid: 5987459
Mohammadinejad P, Abolhassani H, Aghamohammadi A, Pourhamdi S, Ghosh S, Sadeghi B, et al. Class switch recombination process in ataxia telangiectasia patients with elevated serum levels of IgM. J Immunoassay Immunochem. 2015;36:16–26. https://doi.org/10.1080/15321819.2014.891525 .
doi: 10.1080/15321819.2014.891525
pubmed: 24568663
Folgori L, Scarselli A, Angelino G, Ferrari F, Antoccia A, Chessa L, Finocchi A. Cutaneous granulomatosis and combined immunodeficiency revealing Ataxia-Telangiectasia: A case report. Ital J Pediatr. 2010;36:29. https://doi.org/10.1186/1824-7288-36-29 .
doi: 10.1186/1824-7288-36-29
pubmed: 20380744
pmcid: 2857855
van Os NJH, Chessa L, Weemaes CMR, van Deuren M, Fiévet A, van Gaalen J, et al. Genotype-phenotype correlations in ataxia telangiectasia patients with ATM c.3576GA and c.8147TC mutations. J Med Genet. 2019;56:308–16. https://doi.org/10.1136/jmedgenet-2018-105635 .
doi: 10.1136/jmedgenet-2018-105635
pubmed: 30819809
Ludvigsson JF, Neovius M, Hammarström L. Risk of Infections Among 2100 Individuals with IgA deficiency: a nationwide cohort study. J Clin Immunol. 2016;36:134–40. https://doi.org/10.1007/s10875-015-0230-9 .
doi: 10.1007/s10875-015-0230-9
pubmed: 26739713
Weber-Mzell D, Kotanko P, Hauer AC, Goriup U, Haas J, Lanner N, et al. Gender, age and seasonal effects on IgA deficiency: a study of 7293 Caucasians. Eur J Clin Invest. 2004;34:224–8. https://doi.org/10.1111/j.1365-2362.2004.01311.x .
doi: 10.1111/j.1365-2362.2004.01311.x
pubmed: 15025682
Bakhtiar S, Woelke S, Huenecke S, Kieslich M, Taylor AM, Schubert R, et al. Pre-emptive allogeneic hematopoietic stem cell transplantation in ataxia telangiectasia. Front Immunol. 2018;9:2495. https://doi.org/10.3389/fimmu.2018.02495 .
doi: 10.3389/fimmu.2018.02495
pubmed: 30420857
pmcid: 6215822
Shannon CE. The mathematical theory of communication. 1963. MD Comput. 1997;14:306–17.
pubmed: 9230594
O’Connell AE, Volpi S, Dobbs K, Fiorini C, Tsitsikov E, de Boer H, et al. Next generation sequencing reveals skewing of the T and B cell receptor repertoires in patients with wiskott-Aldrich syndrome. Front Immunol. 2014;5:340. https://doi.org/10.3389/fimmu.2014.00340 .
doi: 10.3389/fimmu.2014.00340
pubmed: 25101082
pmcid: 4102881
Leuzzi V, Micheli R, D’Agnano D, Molinaro A, Venturi T, Plebani A, et al. Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia. Neurol Neuroimmunol Neuroinflamm. 2015;2: e98. https://doi.org/10.1212/NXI.0000000000000098 .
doi: 10.1212/NXI.0000000000000098
pubmed: 25884015
pmcid: 4396528
Zielen S, Schubert R. Workshop report: European workshop on ataxia-telangiectasia, Frankfurt, 2011. J Neurogenet. 2011;25:78–81. https://doi.org/10.3109/01677063.2011.592553 .
doi: 10.3109/01677063.2011.592553
pubmed: 21732725
Sanal O, Ersoy F, Yel L, Tezcan I, Metin A, Ozyürek H, et al. Impaired IgG antibody production to pneumococcal polysaccharides in patients with ataxia-telangiectasia. J Clin Immunol. 1999;19:326–34. https://doi.org/10.1023/a:1020599810261 .
doi: 10.1023/a:1020599810261
pubmed: 10535610
Panchakshari RA, Zhang X, Kumar V, Du Z, Wei P-C, Kao J, et al. DNA double-strand break response factors influence end-joining features of IgH class switch and general translocation junctions. Proc Natl Acad Sci U S A. 2018;115:762–7. https://doi.org/10.1073/pnas.1719988115 .
doi: 10.1073/pnas.1719988115
pubmed: 29311308
pmcid: 5789958
Amirifar P, Mozdarani H, Yazdani R, Kiaei F, Moeini Shad T, Shahkarami S, et al. Effect of class switch recombination defect on the phenotype of ataxia-telangiectasia Patients. Immunol Invest. 2020:1–15. https://doi.org/10.1080/08820139.2020.1723104 .
Yazdani R, Latif A, Tabassomi F, Abolhassani H, Azizi G, Rezaei N, Aghamohammadi A. Clinical phenotype classification for selective immunoglobulin A deficiency. Expert Rev Clin Immunol. 2015;11:1245–54. https://doi.org/10.1586/1744666X.2015.1081565 .
doi: 10.1586/1744666X.2015.1081565
pubmed: 26306496
Breedveld A, van Egmond M. IgA and FcαRI: pathological roles and therapeutic opportunities. Front Immunol. 2019;10:553. https://doi.org/10.3389/fimmu.2019.00553 .
doi: 10.3389/fimmu.2019.00553
pubmed: 30984170
pmcid: 6448004
Pasquier B, Launay P, Kanamaru Y, Moura IC, Pfirsch S, Ruffié C, et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: Dual role of FcRgamma ITAM. Immunity. 2005;22:31–42. https://doi.org/10.1016/j.immuni.2004.11.017 .
doi: 10.1016/j.immuni.2004.11.017
pubmed: 15664157
Bagheri Y, Sanaei R, Yazdani R, Shekarabi M, Falak R, Mohammadi J, et al. The Heterogeneous pathogenesis of selective immunoglobulin a deficiency. Int Arch Allergy Immunol. 2019;179:231–46. https://doi.org/10.1159/000499044 .
doi: 10.1159/000499044
pubmed: 31091523
Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: Function, generation, and maintenance. Annu Rev Immunol. 2004;22:745–63. https://doi.org/10.1146/annurev.immunol.22.012703.104702 .
doi: 10.1146/annurev.immunol.22.012703.104702
pubmed: 15032595
Ramiscal RR, Vinuesa CG. T-cell subsets in the germinal center. Immunol Rev. 2013;252:146–55. https://doi.org/10.1111/imr.12031 .
doi: 10.1111/imr.12031
pubmed: 23405902
Amiezer M, Phan TG. Disentangling Tfr cells from Treg cells and Tfh cells: how to untie the Gordian knot. Eur J Immunol. 2016;46:1101–4. https://doi.org/10.1002/eji.201646389 .
doi: 10.1002/eji.201646389
pubmed: 27109022
Morio T, Takahashi N, Watanabe F, Honda F, Sato M, Takagi M, et al. Phenotypic variations between affected siblings with ataxia-telangiectasia: ataxia-telangiectasia in Japan. Int J Hematol. 2009;90:455–62. https://doi.org/10.1007/s12185-009-0408-0 .
doi: 10.1007/s12185-009-0408-0
pubmed: 19705055
Soresina A, Meini A, Lougaris V, Cattaneo G, Pellegrino S, Piane M, et al. Different clinical and immunological presentation of ataxia-telangiectasia within the same family. Neuropediatrics. 2008;39:43–5. https://doi.org/10.1055/s-2008-1076736 .
doi: 10.1055/s-2008-1076736
pubmed: 18504682
Bhatt JM, Bush A, van Gerven M, Nissenkorn A, Renke M, Yarlett L, et al. ERS statement on the multidisciplinary respiratory management of ataxia telangiectasia. Eur Respir Rev. 2015;24:565–81. https://doi.org/10.1183/16000617.0066-2015 .
doi: 10.1183/16000617.0066-2015
pubmed: 26621971
Notarangelo LD, Fischer A, Geha RS, Casanova J-L, Chapel H, Conley ME, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 2009;124:1161–78. https://doi.org/10.1016/j.jaci.2009.10.013 .
doi: 10.1016/j.jaci.2009.10.013
pubmed: 20004777
pmcid: 2797319
Schon K, van Os NJH, Oscroft N, Baxendale H, Scoffings D, Ray J, et al. Genotype, extrapyramidal features, and severity of variant ataxia-telangiectasia. Ann Neurol. 2019;85:170–80. https://doi.org/10.1002/ana.25394 .
doi: 10.1002/ana.25394
pubmed: 30549301
pmcid: 6590299